![](/img/cover-not-exists.png)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
Hodi, F Stephen, Chesney, Jason, Pavlick, Anna C, Robert, Caroline, Grossmann, Kenneth F, McDermott, David F, Linette, Gerald P, Meyer, Nicolas, Giguere, Jeffrey K, Agarwala, Sanjiv S, Shaheen, MontasLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)30366-7
Date:
September, 2016
File:
PDF, 510 KB
english, 2016